NO20040561L - Behandling av lipodystrofi - Google Patents

Behandling av lipodystrofi

Info

Publication number
NO20040561L
NO20040561L NO20040561A NO20040561A NO20040561L NO 20040561 L NO20040561 L NO 20040561L NO 20040561 A NO20040561 A NO 20040561A NO 20040561 A NO20040561 A NO 20040561A NO 20040561 L NO20040561 L NO 20040561L
Authority
NO
Norway
Prior art keywords
treatment
lipodystrophy
renin
inhibitor
prevention
Prior art date
Application number
NO20040561A
Other languages
English (en)
Norwegian (no)
Inventor
John Francis Martin
Jorge D Erusalimsky
Hugh Edward Montgomery
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Publication of NO20040561L publication Critical patent/NO20040561L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20040561A 2001-08-09 2004-02-06 Behandling av lipodystrofi NO20040561L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119460.4A GB0119460D0 (en) 2001-08-09 2001-08-09 The use of inhibitors of the renin-angiotensin system
PCT/GB2002/003639 WO2003013486A1 (en) 2001-08-09 2002-08-07 The treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
NO20040561L true NO20040561L (no) 2004-03-23

Family

ID=9920113

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040561A NO20040561L (no) 2001-08-09 2004-02-06 Behandling av lipodystrofi

Country Status (19)

Country Link
US (1) US7022693B2 (pl)
EP (1) EP1414421B1 (pl)
JP (1) JP2005527462A (pl)
KR (1) KR20040054665A (pl)
CN (1) CN1541094A (pl)
AP (1) AP1731A (pl)
AT (1) ATE411012T1 (pl)
AU (1) AU2002319535B2 (pl)
CA (1) CA2456549A1 (pl)
DE (1) DE60229398D1 (pl)
DK (1) DK1414421T3 (pl)
ES (1) ES2332884T3 (pl)
GB (1) GB0119460D0 (pl)
HU (1) HUP0401041A3 (pl)
MX (1) MXPA04001174A (pl)
NO (1) NO20040561L (pl)
PL (1) PL367941A1 (pl)
WO (1) WO2003013486A1 (pl)
ZA (1) ZA200400887B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0635263A3 (en) * 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin II antagonists (AII) as inhibitors of the growth of adipose tissue.
DE69830069T3 (de) * 1997-10-17 2012-02-09 Ark Therapeutics Ltd. Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
ATE411012T1 (de) 2008-10-15
EP1414421A1 (en) 2004-05-06
GB0119460D0 (en) 2001-10-03
PL367941A1 (pl) 2005-03-07
CA2456549A1 (en) 2003-02-20
AP2004002980A0 (en) 2004-03-31
ZA200400887B (en) 2005-02-03
EP1414421B1 (en) 2008-10-15
ES2332884T3 (es) 2010-02-15
HUP0401041A2 (hu) 2004-08-30
CN1541094A (zh) 2004-10-27
US20040209941A1 (en) 2004-10-21
US7022693B2 (en) 2006-04-04
DK1414421T3 (da) 2008-12-08
HUP0401041A3 (en) 2004-10-28
MXPA04001174A (es) 2005-02-17
AU2002319535B2 (en) 2005-01-06
WO2003013486A1 (en) 2003-02-20
AP1731A (en) 2007-03-30
DE60229398D1 (de) 2008-11-27
KR20040054665A (ko) 2004-06-25
JP2005527462A (ja) 2005-09-15

Similar Documents

Publication Publication Date Title
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
DK1412357T3 (da) Beta-aminotetrahydroimidazo-(1,2-a)-pyraziner og tetrahydrotriazolo-(4,3-a)-pyraziner som dipeptidylpeptidaseinhibitorer til behandling eller forebyggelse af diabetes
DE69909756D1 (de) Antivirale pyrimidinderivate
TR200201187T2 (tr) Ters transkriptazın inhibitörleri olarak benzofenonlar
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20063958L (no) HIV integrase inhibitorer
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
TR200103216T2 (tr) Pirimidinon bileşimleri
NO20032831D0 (no) Pyrimidinaminer som angiogenese-modulatorer
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
ATE312096T1 (de) Neue verbindungen
NO993670L (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikamenter for behandling av AIDS
SE0302304D0 (sv) Novel compounds
DK1392355T3 (da) Anvendelse af proteasominhibitorer tilbehandling af öjentörhedslidelser
TR199801289T2 (en) Terap�tik bile�ikler.
WO2003061704A3 (en) Combination therapy for the treatment of bacterial infections
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application